Saumil Gandhi, M.D., Ph.D.

Peer-Reviewed Articles

1. Azhar M, Abrencillo R, Gandhi S, Altan M, Sheshadri A. Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease. Curr Opin Pulm Med 29(4):248-255, 2023. e-Pub 2023. PMID: 37170920.
2. Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health 5(7):e404-e420, 2023. e-Pub 2023. PMID: 37268451.
3. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. e-Pub 2023. PMID: 37478883.
4. Hu Y, Paris S, Sahoo N, Bertolet G, Wang Q, Wang Q, Barsoumian HB, Da Silva J, Huang A, Doss DJ, Pollock DP, Hsu E, Selene N, Leyton CSK, Voss TA, Masrorpour F, Ganjoo S, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection. JCI Insight 8(12), 2023. e-Pub 2023. PMID: 37345658.
5. Altan M, Soto F, Zhong LL, Akhmedzhanov FO, Wilson NR, Zarifa A, Albittar AA, Yang V, Lewis J, Rinsurongkawong W, Jack Lee J, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Jennings K, Khawaja F, Faiz SA, Shannon VR, Shroff G, Godoy MCB, Daver NG, Gandhi S, Mendoza TR, Naing A, Daniel-MacDougall C, Heymach JV, Sheshadri A. Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. Oncologist. e-Pub 2023. PMID: 37156009.
6. Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun 14(1):695, 2023. e-Pub 2023. PMID: 36755027.
7. De B, Farooqi AS, Mitchell KG, Ludmir EB, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Swisher SG, Gibbons DL, Zhang J, Le X, Elamin YY, Gomez DR, Ning MS, Lin SH, Liao Z, Chang JY, Vaporciyan AA, Heymach JV, Antonoff MB, Gandhi SJ. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol 7:e2200540, 2023. PMID: 36716413.
8. Khan TM, Verbus EA, Gandhi SJ, Heymach JV, Hernandez JM, Elamin YY. Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR). Annals of Surgical Oncology, 2022.
9. Antonoff MB, Feldman HA, Mitchell KG, Farooqi A, Ludmir EB, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Sepesi B, Swisher SG, Walsh GL, Gandhi SJ, Gomez DR, Vaporciyan AA. Surgical Complexity of Pulmonary Resections Performed for Oligometastatic NSCLC. JTO Clinical and Research Reports 3(3), 2022.
10. Maroongroge S, Weissferdt A, Buszek S, Rice DC, Smith BD, Gandhi SJ,. Management of Bronchial Adenoma/Ciliated Muconodular Papillary Tumor with Definitive Stereotactic Body Radiation Therapy (SBRT): A Case Report. Clinical Lung Cancer 23(5), 2022.
11. Hu Y, Paris S, Barsoumian H, Abana CO, He K, Sezen D, Wasley M, Masrorpour F, Chen D, Yang L, Dunn JD, Gandhi S, Nguyen Q, Cortez MA, Welsh JW. A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model. Journal of Nanobiotechnology, 2021.
12. Wang X, Hobbs B, Gandhi SJ, Muijs CT, Langendijk JA, Lin SH. Current status and application of proton therapy for esophageal cancer. Radiotherapy and Oncology 164:27-36, 2021.
13. Abana CO, Hu Y, Paris S, Barsoumian HB, Gandhi S, Nguyen QN, Cortez MA, Welsh JW. NBTXR3 Nanoparticle With Immunoradiation Might Reshape Metastatic Tumor-Infiltrating T Cell Repertoire in Murine Lung Cancer Model. International Journal of Radiation Oncology*Biology*Physics 111(3):e419-e420, 2021.
14. He K, Comeaux NI, Tang C, Ning MS, Hong DS, Heymach J, Nguyen QN, Chang JY, Gandhi S, Diab A, Blumenschein GR, Glitza I, Chun SG, Lee P, Fossella FV, Welsh JW. Phase II Clinical Trial Evaluating Complete Metastasis Ablation After Progression on Checkpoint Inhibition. International Journal of Radiation Oncology*Biology*Physics 111(3):e471-e472, 2021.
15. He K, Patel RR, Barsoumian HB, Chang JY, Tang C, Comeaux NI, Ning MS, Gandhi S, Davies M, Glitza I, Hong DS, Heymach J, Nguyen QN, Diab A, Chun SG, Lee P, Blumenschein GR, Fossella FV, Chen D, Welsh JW. Phase II Trial of High-Dose Radiotherapy vs. Low-Dose Radiation, Demonstrating Low-Dose Mediated Immune-Cell Infiltration. International Journal of Radiotherapy and Oncology*Biology*Physics 111(3):S118, 2021.
16. Hu Y, Paris S, Barsoumian HB, Abana CO, He K, Wasley M, Younes AI, Masrorpour F, Chen D, Yang L, Dunn JD, Zhang J, Gandhi S, Nguyen Q, Cortez MA, Welsh JW. Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects. International Journal of Radiation Oncology*Biology*Physics 111(3):647-657, 2021.
17. Farooqi A, Ludmir EB, Mitchell KG, Antonoff MB, Tang C, Lee P, Chang J, Elamin Y, Gomez DR, Gandhi SJ. Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC. Radiotherapy and Oncology 163:114-118, 2021.
18. Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA, Antonoff M, Hofstetter W, Rajaram R, Rice D, Sepesi B, Swisher S, Vaporciyan A, Walsh G, DeGraaf C, Correa A, Chen A, Gandhi S, Ritsuko K, Lee P, Nguyen Q, Ning M, Gao S, Pollard-Larkin J, Nitsch P, Sadagopan R, Wang X. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. The Lancet Oncology 22(10):1448-1457, 2021.
19. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen Q, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter W, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiotherapy and Oncology 162:60-67, 2021.
20. Boyce-Fappiano D, Nguyen Q, Chapman BV, Allen PK, Gjyshi O, Pezzi TA, De B, Gomez D, Lin SH, Chang JY, Liao Z, Lee P, Gandhi SJ. Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non–small-cell Lung Cancer. Clinical Lung Cancer 22(5):e745-e755, 2021.
21. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol 162:60-67. e-Pub 2021. PMID: 34237343.
22. Hu Y, Paris S, Barsoumian H, Abana CO, He K, Wasley M, Younes A, Masrorpour F, Chen D, Yang L, Dunn JD, Zhang J, Gandhi S, Nguyen QN, Cortez MA, Welsh J. Radiotherapy enhanced by NBTXR3 nanoparticles overcomes anti-PD1 resistance and evokes abscopal effects. Int J Radiat Oncol Biol Phys. e-Pub 2021. PMID: 34242713.
23. Xu T, Meng QH, Gilchrist SC, Lin SH, Lin R, Tucker S, Xu T, Milgrom SA, Gandhi SJ, Wu H, Zhao Y, Lopez-Mattei JC, Mohan R, Liao Z. Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiotherapy-Induced Cardiotoxicity in Non-Small Cell Lung Cancer Patients: A Secondary Analysis of a Prospective Randomized Trial. Int J Radiat Oncol Biol Phys. e-Pub 2021. PMID: 34302893.
24. Chapman BV, Ning MS, Farnia B, Mesko S, Lin SH, Tang C, Allen PK, Liao Z, Chang JY, Komaki R, Mehran RJ, Gandhi SJ, Gomez DR. Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clinical Lung Cancer 22(3):225-233.e7, 2021.
25. Chapman BV, Ning MS, Farnia B, Mesko S, Lin SH, Tang C, Allen PK, Liao Z, Chang JY, Komaki R, Mehran RJ, Gandhi SJ, Gomez DR. Postoperative radiotherapy for locally advanced NSCLC: Implications for shifting to conformal, high-risk fields. Clin Lung Cancer 22(3):225-233.e7, 2021. e-Pub 2020. PMID: 32727706.
26. Jing W, Liu Y, Zhu H, Welsh JW, Gandhi S, Jeter M, Nguyen Q, Chen AB, O'Reilly M, Liao Z, Chang JY, Lee P, Lin SH. Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clinical and Translational Radiation Oncology 28:54-61, 2021.
27. Jing W, Liu Y, Zhu H, Welsh J, Gandhi S, Jeter M, Nguyen Q, Chen AB, O'Reilly M, Liao Z, Chang JY, Lee P, Lin SH. Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clin Transl Radiat Oncol 28:54-61, 2021. e-Pub 2021. PMID: 33778173.
28. Mitchell JG, Farooqi A, Ludmir EB, Corsini EM, Sepesi B, Gomez DR, Antonoff MB, Vaporciyan AA, Swisher SG, Heymach JV, Zhang J, Gandhi SJ. Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer. The Journal of Thoracic and Cardiovascular Surgery 161(4):1497-1504.e2, 2021.
29. Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu R, Zhang Z, Heymach JV, Fossella FV, Lu C, Nguyen Q, Liao Z. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. Journal of Thoracic Oncology 16(2):269-277, 2021.
30. Patel RR, Verma V, Barsoumian HB, Ning MS, Chun SG, Tang C, Chang JY, Lee PP, Gandhi S, Balter P, Dunn JD, Chen D, Puebla-Osorio N, Cortez MA, Welsh JW. Use of Multi-Site Radiation Therapy for Systemic Disease Control. International Journal of Radiation Oncology*Biology*Physics 109(2):352-364, 2021.
31. Boyce-Fappiano D, Nguyen QN, Chapman BV, Allen PK, Gjyshi O, Pezzi TA, De B, Gomez D, Lin SH, Chang JY, Liao Z, Lee P, Gandhi SJ. Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer. Clin Lung Cancer. e-Pub 2021. PMID: 33707003.
32. Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, Fossella FV, Lu C, Nguyen QN, Liao Z. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol 16(2):269-277, 2021. e-Pub 2020. PMID: 33198942.
33. Patel RR, Verma V, Barsoumian HB, Ning MS, Chun SG, Tang C, Chang JY, Lee PP, Gandhi S, Balter P, Dunn JD, Chen D, Puebla-Osorio N, Cortez MA, Welsh JW. Use of Multi-Site Radiation Therapy for Systemic Disease Control. Int J Radiat Oncol Biol Phys 109(2):352-364, 2021. e-Pub 2020. PMID: 32798606.
34. Mesko S, Ning MS, Lakomy D, Verma V, Chang JY, O'Reilly M, Jeter MD, Gandhi SJ, Lin SH, Nguyen QN, Liao Z, Welsh J, Chen AB, Hahn S, Gomez DR. Thoracic radiation oncology clinical trial accrual and reasons for nonenrollment: Results of a large, prospective, multiyear analysis. Int J Radiat Oncol Biol Phys 107(5):897-908, 2020. e-Pub 2020. PMID: 32360653.
35. Rajaram R, Correa AM, Xu T, Nguyen QN, Antonoff MB, Rice D, Mehran R, Roth J, Walsh G, Swisher S, Hofstetter WL, Vaporciyan A, Cascone T, Tsao AS, Papadimitrakopoulou VA, Gandhi S, Liao Z, Sepesi B. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer 21(4):e294-e301, 2020. e-Pub 2020. PMID: 32089476.
36. Pezzi TA, Ning MS, Thaker NG, Boyce-Fappiano D, Gjyshi O, Olivieri ND, Guzman AB, Incalcaterra JR, Mesko S, Gandhi S, Chun S, Tang C, Frank SJ, Gomez DR. Evaluating single-institution resource costs of consolidative radiotherapy for oligometastatic non-small cell lung cancer using time-driven activity-based costing. Clin Transl Radiat Oncol 23:80-84, 2020. e-Pub 2020. PMID: 32529054.
37. Ayoub Z, Ning MS, Brooks ED, Kang J, Welsh JW, Chen A, Gandhi S, Heymach JV, Vaporciyan AA, Chang JY. Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys 107(2):261-269, 2020. e-Pub 2020. PMID: 32044413.
38. Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, Mehran RJ, Koong AC, Gandhi SJ, Hofstetter WL, Hong TS, Delaney TF, Liao Z, Mohan R. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. J Clin Oncol 38(14):1569-1579, 2020. e-Pub 2020. PMID: 32160096.
39. Nantavithya C, Gomez DR, Chang JY, Mohamed ASR, Fuller CD, Li H, Brooks ED, Gandhi SJ. An improved method for analyzing and reporting patterns of in-field recurrence after stereotactic ablative radiotherapy in early-stage non-small cell lung cancer. Radiother Oncol 145:209-214, 2020. e-Pub 2020. PMID: 32062325.
40. Pezzi TA, Schwartz DL, Pisters KMW, Mohamed ASR, Welsh JW, Chang JY, Liao Z, Gandhi SJ, Byers LA, Minsky BD, Fuller CD, Chun SG. Association of medicaid insurance with survival among patients with small cell lung cancer. JAMA Netw Open 3(4):e203277, 2020. e-Pub 2020. PMID: 32320035.
41. Awobajo MD, Vaporciyan AA, Lu C, Gandhi SJ. Stereotactic body radiation therapy (SBRT) in the management of pulmonary spindle cell carcinoma. BMJ Case Rep 13(4), 2020. e-Pub 2020. PMID: 32327465.
42. Li H, Verma V, Brooks ED, Feng L, Zhang T, Welsh JW, Lin SH, Gomez D, Gandhi SJ, Heymach JV, Chang JY. Impact of corticosteroid administration on outcomes following stereotactic ablative radiotherapy for non-small-cell lung cancer. Clin Lung Cancer 20(4):e480-e488, 2019. e-Pub 2019. PMID: 31078421.
43. Liao Z, Gandhi SJ, Lin SH, Bradley J. Does proton therapy offer demonstrable clinical advantages for treating thoracic tumors?. Semin Radiat Oncol 28(2):114-124, 2018. PMID: 29735187.
44. Flynn JP, O'Hara MH, Gandhi SJ. Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). Transl Lung Cancer Res 6(2):159-168, 2017. PMID: 28529898.
45. Pignatelli J, Bravo-Cordero JJ, Roh-Johnson M, Gandhi SJ, Wang Y, Chen X, Eddy RJ, Xue A, Singer RH, Hodgson L, Oktay MH, Condeelis JS. Macrophage-dependent tumor cell transendothelial migration is mediated by Notch1/MenaINV-initiated invadopodium formation. SCi Rep 6:37874, 2016.
46. Gandhi SJ, Minn AJ, Vonderheide RH, Wherry EJ, Hahn SM, Maity A. Awakening the immune system with radiation: optimal dose and fractionation. Cancer Lett 368(2):185-90, 2015. e-Pub 2015. PMID: 25799953.
47. Gandhi SJ, Liang X, Ding X, Zhu TC, Ben-Josef E, Plastaras JP, Metz JM, Both S, Apisarnthanarax S. Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: Photons versus protons. Pract Radiat Oncol 5(4):209-18, 2015. e-Pub 2015. PMID: 25703530.
48. Gandhi SJ. Transcription of functionally related constitutive genes is not coordinated. Nat Struct Mol Biol 18(1):27-34, 2011.
49. Silverman SJ, Petti AA, Slavov N, Parsons L, Briehof R, Thiberge SY, Zenklusen D, Gandhi SJ, Larson DR, Singer RH, Botstein D.. Metabolic cycling in single yeast cells from unsynchronized steady state populations limited on glucose or phosphat. Proc Natl Acad Sci USA 107(15):6946-6951, 2010.
50. Pezo RC, Gandhi SJ, Shirley LA, Pestell RG, Augenlicht LH, Singer RH. Single-­cell transcription-­site activation predicts chemotherapy response in human colorectal tumors. Cancer Res 68(13):4977-4982, 2008.
51. Motz JT, Fitzmaurice M, Miller A, Gandhi SJ, Haka AS, Galindo LH, Dasari RR, Kramer JR, Feld MS. In vivo raman spectral pathology of human atherosclerosis and vulnerable plaque. J Biomed Opt 11(2):021003, 2006.
52. Motz JT, Gandhi SJ, Scepanovic OR, Haka AS, Kramer JR, Dasari RR, Feld MS. Real-time raman system for in vivo disease diagnosis. J Biomed Opt 10(3):031113-1, 2005.

Other Articles

1. Ting Xu, Qing H. Meng, Susan C. Gilchrist, Steven H. Lin, Ruitao Lin, Tianlin Xu, Sarah A. Milgrom, Saumil J. Gandhi, Haijun Wu, Yu Zhao, Juan C. Lopez-Mattei, Radhe Mohan, Zhongxing Liao Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiation Therapy-Induced Cardiotoxicity in Patients with Non-Small Cell Lung Cancer: A Secondary Analysis of a Prospective Randomized Trial. International Journal of Radiation Oncology 111(4):907-916, 2021.

Abstracts

1. Liu Y, Zhang Z, Rinsurongkawong W, Gay CM, Le X, Ning MS, Lewis J, Rinsurongkawong V, Lee J, Roth J, Swisher S, Gandhi SJ, Lee PP, Gibbons DL, Vaporciyan AA, Heymach JV, Zhang J, Lin SH. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Network, 2022.
2. Shaitelman SF, Gandhi SJ, DeSnyder S, Smith GL, Lin R, Barcenas C, Stauder MC, Hoffman KE, Strom EA, Ferguson S, Smith BD, Woodward BS, Perkins GH, Mitchell MP, Goodman CR, Aldrich M, Travis M, Lilly S, Bedrosian I. Prospective, Longitudinal Assessment of Lymphedema-related Quality of Life for Locally Advanced Breast Cancer Patients: A Foundation for Needed Elements in a Lymphedema Screening Program. American Radium Society 2022 Annual Meeting, 2022.
3. Chapman, BV; Farnia, B; Ning, MS; Allen, P; Lin, SH; Liao, ZX; Gandhi, SJ; Gomez, D. Patterns of failure after postoperative radiation therapy for locally advanced NSCLC: implications for shifting toward More conformal radiation fields. Int J Radiat Oncol Biol Phys 101(2):E2-E3, 2018.
4. Gandhi SJ, Liang X, Ding, X, Zhu TC, Ben Josef E, Plastaras JP, Metz JM, Both S, Apisarnthanarax S. Development of a decision tree analysis tool for optimal delivery of liver stereotactic body radiation therapy: photons versus protons. Int J Radiat Oncol Biol Phys 87(2):S326, 2013.
5. Gandhi SJ, Larson DR, Hocine S, Singer RH, Zenklusen D.. Singer RH, Zenklusen D. Studying gene expression dynamics in yeast – a single molecule approach, 2010.
6. Gandhi SJ, Zenklusen D, Singer RH.. Transcripts of functionally related genes in individual S. cerevisiae cells are uncorrelated due to stochastic fluctuations, 2009.